HSK39004

Phase 2Small molecule

HSK39004 is one of 125 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

124

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

TicsActive, not recruiting

Safety and EfficacyNot yet recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

TicsPhase 2

Active, not recruiting

Safety and EfficacyPhase 2

Not yet recruiting

Competition

Competitive Landscape

149 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

8 2

Opdivo

Bristol-Myers Squibb

Phase 3

7 3

Humira

Novartis

Phase 3

3 4

Avastin

Roche

Phase 3

3 5

BEYFORTUS

Sanofi

Phase 3

1 6

Adriamycin

Pfizer

Phase 3

1 7

Oncovin

Eli Lilly

Phase 3

1 8

Neulasta

Amgen

Phase 3

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

6 10

Rayos

RRoxane Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Not yet recruiting

Chronic Obstructive Pulmonary Disease

NCT07108699

Q3 2027

Phase 2Not yet recruiting

Safety and Efficacy

NCT07425210

Clinical

Trials by Indication[1]

Clinical Trial2 trials

Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of HSK39004 Suspension for Inhalation

Completed· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT06905847·63 enrolled

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation

Completed· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT06971198·26 enrolled

Chronic Obstructive Pulmonary Disease2 trials

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Active, not recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07140328·50 enrolled

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Not yet recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07108699·180 enrolled

Safety and Efficacy1 trial

Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD

Not yet recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07425210·300 enrolled

Tics1 trial

A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients

Active, not recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07331402·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for HSK39004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HSK39004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HSK39004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Haisco Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Haisco Pharmaceutical Group Co., Ltd.

HSK39004

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Trials by Indication[1]

Clinical Trial2 trials

Chronic Obstructive Pulmonary Disease2 trials

Safety and Efficacy1 trial

Tics1 trial

References

Drug Info

Quick Facts

Related News